Showing 1641-1650 of 1691 results for "".
- FDA Approves Solriamfetol for Treatment of Excessive Daytime Sleepinesshttps://practicalneurology.com/news/httpswwwfdagovdrugsdefaulthtm/2468797/The Food and Drug Administration (FDA) has approved solriamfetol (Sunosi; Jazz Pharmaceuticals, Dublin, Ireland) for the treatment of adults with excessive daytime sleepiness (EDS)associated with narcolepsy or obstructive sleep apnea (OSA). Solriamfetol is a dual dopamine and norepinephrine reupt
- New CPT Code for Electrocorticography From Responsive Neurostimulatorhttps://practicalneurology.com/news/new-cpt-code-for-electrocorticography-from-responsive-neurostimulator/2468834/The American Medical Association (AMA) has issued a new Category/Current Procedural Terminology (CPT) code for electrocorticography from an implanted brain neurostimulator. The code applies to services that physicians perform with a responsive neurostimulator (RNS System; NeuroPace, Mountain
- New Drug Application Submitted for Low-Dose Fenfluramine for Treatment of Dravet Syndromehttps://practicalneurology.com/news/new-drug-application-submitted-for-low-dose-fenfluramine-for-treatment-of-dravet-syndrome/2468849/A new drug application (NDA) has been submitted to the Food and Drug Administration (FDA) for low-dose fenfluramine (Fintepla, previously known as ZX008; Zogenix, Emeryville, CA) for the treatment of seizures associated with Dravet syndrome. The NDA is based on data from 2 phase 3 clinical trials
- Practical Neurology Nominated as Finalist for 2 Eddie & Ozzie Awardshttps://practicalneurology.com/news/practical-neurology-nominated-as-finalist-for-2-eddie-ozzie-awards/2470285/Practical Neurology has been named a finalist for 2 categories in the 2023 Folio: Eddie & Ozzie Awards, a prestigious recognition program organized by Folio, a magazine industry–focused publication. Eddies are awarded on the basis of editorial excellence in publication
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Ted Pigeon, Editor-in-Chiefhttps://practicalneurology.com/profiles/ted-pigeon-editor-in-chief/OKA8zb/
- Column Editor: Abhi Pandhi, MDhttps://practicalneurology.com/profiles/column-editor-abhi-pandhi-md/jVmGa6/
- Column Editor: William S. David, MD, PhDhttps://practicalneurology.com/profiles/column-editor-william-s-david-md-phd/LxAR65/
- Column Editor: Waimai Amy Tan, MDhttps://practicalneurology.com/profiles/column-editor-waimai-amy-tan-md/Lgynr8/
- Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel Pharmaceuticals plchttps://practicalneurology.com/profiles/jennifer-gudeman-pharmd-senior-vice-president-medical-and-clinical-affairs-of-avadel-pharmaceuticals-plc/LAJ1R1/